Multiple sclerosis-modifying therapies: view in the future

Abstract

Multiple sclerosis is a chronic disabling disease of the central nervous system, afflicting mainly young people. The efforts of investigators around the world are aimed at creating highly effective disease-modifying therapies that have a favorable safety and tolerance profile. The review briefly lists the disease-modifying therapies currently registered in the Russian Federation. Information is provided on the international clinical trial phases II and III of disease-modifying therapies, international nonproprietary products and/or active substance molecules, intended mechanisms of action and indicators of their effectiveness and safety. The article describes disease-modifying therapies that have been approved by the FDA and that may be available for Russian neurologists in the near future for the treatment of multiple sclerosis. The treatment possibilities of drugs used in Russia for other indications than multiple sclerosis are discussed.

Clinical and Neurological Features Depending on the Side of Localization in Patients With Ischemic Stroke

“…It has been established that the connection between the cortical part of the brain and the brainstem is different. In right-handed people, the right hemisphere is more closely connected with the diencephalic region, which is responsible for autonomic, humoral, and endocrine regulation [1]. Paired brain structures are in close interaction, which determines the heterogeneity of functional asymmetry in individuals.…”